EUVIMEDEUVIMED entdecken
Crossref

The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy

Van Khanh Nguyen iD, Kosuke Matsui iD, Hisashi Kosaka iD, Hideyuki Matsushima, Hidekazu Yamamoto iD, Gozo Kiguchi, Takuya Ohigashi, Thanh Tung Lai iD, Hoang Hai Duong, Kyoko Inoue, Moriyasu Takada, Fujimasa Tada iD und 14 weitere

Hepatology Research · 2026-06 · 56 (6) · 988-997

DOI: 10.1111/hepr.70152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 21.03.2026. Verfasst von Van Khanh Nguyen und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Kansai Medical University, Osaka, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

We aimed to determine the associations between the pretreatment Advanced Lung Cancer Inflammation Index (ALI) and survival outcomes in patients with unresectable hepatocellular carcinoma (u‐HCC) who received atezolizumab plus bevacizumab (Atez/Bev).

Methods

This retrospective study analyzed 563 patients with u‐HCC who were treated with Atez/Bev (Sept 2020–Dec 2024). The ALI was calculated according to Body Mass Index × serum albumin level/neutrophil‐to‐lymphocyte ratio. Associations between ALI and overall survival (OS) and progression‐free survival (PFS) were evaluated by Cox proportional hazards regression analysis.

Results

An ALI cutoff value of 27.04, determined by receiver operating characteristic curve analysis, was used to classify patients into low‐ and high‐ALI groups. High‐ALI patients had longer median OS (26.1 vs. 13.7 months, p < 0.001) and PFS (9.3 vs. 5.2 months, p < 0.001), and a higher disease control rate (82.5% vs. 69.1%, p < 0.001) compared to low‐ALI patients. Multivariate Cox regression analysis confirmed that a high ALI value was a significant prognostic marker for OS (hazard ratio [HR] 0.69, 95% confidence interval [CI] 0.54–0.88, p = 0.003) and PFS (HR: 0.75, 95% CI: 0.61–0.92, p = 0.006). Subgroup analyses showed that the trend toward improved outcomes was consistent for high ALI values in all clinically relevant subgroups.

Conclusions

A high pretreatment ALI value was associated with improved survival and disease control in u‐HCC patients receiving Atez/Bev, underscoring its potential utility as a prognostic marker for clinical management and further studies.

Schlagwörter

Stichwörter der Autor:innen

atezolizumabbevacizumabhepatocellular carcinomaprognosis

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Kansai Medical University, Osaka, Japan.
  • Internal Gastroenterology Department, VNU University of Medicine and Pharmacy, Hanoi, Vietnam.
  • Department of Surgery, Hanoi Medical University, Hanoi, Vietnam.
  • Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
  • Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.

ORCID-Profile: Van Khanh Nguyen, Kosuke Matsui, Hisashi Kosaka, Hidekazu Yamamoto, Thanh Tung Lai, Fujimasa Tada, Takeshi Hatanaka, Toshifumi Tada, Ei Itobayashi, Hidenori Toyoda, Takashi Kumada

Zitieren

APA

Nguyen, V. K., Matsui, K., Kosaka, H., Matsushima, H., Yamamoto, H., Kiguchi, G., Ohigashi, T., Lai, T. T., Duong, H. H., Inoue, K., Takada, M., Tada, F., Hiraoka, A., Hatanaka, T., Tada, T., Itobayashi, E., Toyoda, H., Tani, J., Kato, H., …, & Kaibori, M. (2026). The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy. Hepatology Research, 56(6), 988-997. https://doi.org/10.1111/hepr.70152

Vancouver

Nguyen VK, Matsui K, Kosaka H, Matsushima H, Yamamoto H, Kiguchi G, et al. The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy. Hepatology Research. 2026;56(6):988-997. doi:10.1111/hepr.70152

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Van Khanh and Matsui, Kosuke and Kosaka, Hisashi and Matsushima, Hideyuki and Yamamoto, Hidekazu and Kiguchi, Gozo and Ohigashi, Takuya and Lai, Thanh Tung and Duong, Hoang Hai and Inoue, Kyoko and Takada, Moriyasu and Tada, Fujimasa and Hiraoka, Atsushi and Hatanaka, Takeshi and Tada, Toshifumi and Itobayashi, Ei and Toyoda, Hidenori and Tani, Joji and Kato, Hiroki and Yoshii, Kengo and Shiba, Shunsuke and Yamaguchi, Takashi and Shimoda, Shinji and Kumada, Takashi and Naganuma, Makoto and Kaibori, Masaki},
  title = {The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy},
  journal = {Hepatology Research},
  year = {2026},
  volume = {56},
  number = {6},
  pages = {988--997},
  doi = {10.1111/hepr.70152}
}
Kostenlos starten →